Every Form 4 that Vor Biopharma Inc. (VOR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.
Vor Biopharma Inc. (VOR) reported that entities associated with RA Capital Management, L.P., a ten percent owner, effected an exercise of a stock option for 1,500 shares of Common Stock on August 24, 2026. The option, with an exercise price of $3.736 per share, was immediately exercisable and is now fully exercised with 0 options remaining for this grant.
The option had been granted to non-employee director Joshua Resnick under Vor Biopharma’s director compensation policy, but under his arrangement with RA Capital, any stock received upon exercise is turned over to RA Capital Management, offsetting advisory fees owed by RA Capital Healthcare Fund, L.P. The Adviser, its general partner, the Fund, and individuals Peter Kolchinsky and Rajeev Shah all disclaim beneficial ownership of the option and underlying shares except for any pecuniary interest. The exercise terms reflect a 1-for-20 reverse stock split effected by Vor Biopharma on September 18, 2025.
RA Capital Healthcare Fund LP, an affiliate of RA Capital Management and a 10% owner of Vor Biopharma, exercised pre-funded warrants for 2,100,000 common shares at $0.002 per share. The exercise was cashless, so 213 shares valued at $19.75 were withheld to pay the exercise price and 2,099,787 shares were issued to the Fund. Following the transaction, the Fund continued to hold 7,900,000 pre-funded warrants, which are immediately exercisable with no expiration but subject to a 19.99% beneficial ownership cap. RA Capital Management, its general partner, and Dr. Peter Kolchinsky and Mr. Rajeev Shah disclaim beneficial ownership beyond their pecuniary interest, and the securities are held directly by the Fund.
Vor Biopharma director David Zaccardelli received a new stock option grant. The award covers 42,658 options to buy Vor Biopharma common stock at an exercise price of $20.10 per share and expires on July 6, 2036. These options will vest in 36 equal monthly installments beginning on August 7, 2026, contingent on his continued service with the company.
Vor Biopharma Inc. reported a Form 4 showing a stock option grant related to Dr. Andrew Levin, connected with RA Capital. The option covers 57,162 shares of Vor Biopharma common stock at an exercise price of $14.09 per share, expiring on June 10, 2036. One thirty-sixth of the option vests on July 11, 2026 and then monthly, as long as Dr. Levin continues in service. Under his arrangement with the adviser, the option is held for the benefit of RA Capital Healthcare Fund, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Vor Biopharma Inc. director Michel Detheux received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. These are compensation-related awards, not open-market purchases.
One thirty-sixth of the option grant will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, conditioned on Detheux’s continued service. Following this award, he holds options for 57,162 shares directly according to this filing.
Vor Biopharma Inc. director Fouad Namouni received a grant of stock options covering 56,549 shares of common stock. The options have an exercise price of $14.0900 per share and expire on June 10, 2036. One thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional portions vesting monthly thereafter, contingent on his continued service. Following this grant, he holds 56,549 stock options directly.
Vor Biopharma director Wouter Joustra received a stock option grant covering 57,162 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 10, 2036. One thirty-sixth of the award vests monthly starting July 11, 2026, contingent on continued service. Following this compensation-related grant, Joustra holds 57,162 options directly and there were no open-market buys or sales reported.
Vor Biopharma Inc. director Erez Kalir received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. One thirty-sixth of the options vest on July 11, 2026 and then monthly thereafter, subject to continued service, so the award vests over three years. Following this grant, the reported derivative holdings from this award total 57,162 options held directly.
Vor Biopharma Inc. reported that director Alexander Cumbo received a grant of stock options on Common Stock as part of his compensation. The award covers 56,345 options with an exercise price of $14.09 per share, all held directly.
These options expire on June 10, 2036 and relate to 56,345 underlying shares of Common Stock. According to the vesting terms, one thirty-sixth of the options will vest and become exercisable on July 11, 2026 and each month thereafter, conditioned on Mr. Cumbo’s continued service through each vesting date.
Vor Biopharma director Daniella Beckman received a grant of 53,283 stock options to buy Vor Biopharma common stock at an exercise price of $14.09 per share. These options were awarded as compensation and are held directly.
According to the vesting schedule, one thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, as long as she continues to serve the company. After this grant, she holds stock options covering 53,283 underlying shares, which will expire on June 10, 2036 if not exercised.
Vor Biopharma Inc. reported that director Andrew David Levin was granted a stock option covering 57,162 shares of common stock at an exercise price of $14.09 per share. The option expires on June 10, 2036 and is a compensation-related award.
One thirty-sixth of the option vests and becomes exercisable each month starting on July 11, 2026, subject to his continued service. Under an arrangement with RA Capital Management, L.P., Levin holds this option for the benefit of the RA Capital Healthcare Fund, L.P. and is obligated to turn over any net cash or stock received, and he therefore disclaims beneficial ownership of the option and underlying shares.
Vor Biopharma Inc. reported an open‑market sale of its common stock by entities associated with RA Capital. On April 22, 2026, RA Capital Healthcare Fund LP sold 165,150 shares of Vor Biopharma common stock at a weighted average price of $15.77, through multiple trades between $15.75 and $15.85. After these transactions, the fund continued to hold 2,402,095 shares indirectly reported. RA Capital Management, L.P., its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests.
Vor Biopharma Inc. reported that an investment vehicle associated with RA Capital executed open-market sales of its Common Stock. On April 17, 2026, the RA Capital Healthcare Fund LP sold 458,411 shares at a weighted average price of $16.28 per share, in multiple trades between $15.95 and $16.85.
On April 20, 2026, the Fund sold an additional 171,963 shares at a weighted average price of $15.77 per share, with individual trades between $15.75 and $16.00. Following these transactions, the Fund held 2,567,245 shares of Vor Biopharma common stock indirectly, and RA Capital Management, its general partner and principals disclaim beneficial ownership beyond their pecuniary interests.
Vor Biopharma Inc. insider entities associated with RA Capital reported open-market sales of an aggregate 737,989 shares of Common Stock over three days at weighted average prices around $16 per share. The shares are held directly by RA Capital Healthcare Fund, L.P., for which RA Capital Management, L.P. is investment manager.
After these transactions, the reporting entities continue to hold 3,197,619 shares of Vor Biopharma common stock indirectly. RA Capital Management, its general partner, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
RA Capital Healthcare Fund LP, an entity associated with RA Capital Management, reported open-market sales of Vor Biopharma common stock over three days. The filings show indirect sales totaling 620,133 shares of Common Stock on April 8–10, 2026, at weighted average prices between $15.75 and $16.98 per share, executed in multiple trades within those ranges. After these transactions, the reporting group indicates indirect ownership of 3,935,608 shares. The Adviser, its general partner, the Fund, and individuals Peter Kolchinsky and Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
RA Capital Healthcare Fund LP, through RA Capital Management, reported open-market sales of Vor Biopharma common stock. On April 2 and April 6, the Fund sold a total of 849,257 shares at prices ranging from $16.25 to $19.09 per share, using weighted-average pricing for each trade block.
After these transactions, the Fund indirectly held 4,555,741 Vor Biopharma shares, with RA Capital Management and related principals disclaiming beneficial ownership beyond their pecuniary interests. All reported holdings are described as being held directly by the Fund.
Vor Biopharma Inc. reported an insider equity update involving its officer serving as CFO. On December 5, 2025, the company’s compensation committee approved the cancellation of 694,137 restricted stock units, leaving the reporting person with no directly held common stock after the transaction.
On the same date, the CFO acquired an employee stock option covering 1,388,274 shares of common stock, expiring on December 4, 2035. The exercise price is $17.80 per share, or $8.18 per share if the option is exercised after a defined “Retention Period” that runs from December 5, 2025 through the earlier of December 5, 2027 or a qualifying change in control during continuous service. One quarter of the option vests on July 1, 2026, with the rest vesting in equal monthly installments over three years, subject to continued service. Share counts reflect a 1-for-20 reverse stock split completed on September 18, 2025.
Vor Biopharma (VOR): RA Capital-affiliated reporting persons, identified as a director and 10% owner, reported open-market sales of common stock on October 28–30, 2025.
Disclosed transactions: 87,828 shares at a weighted average price of $27.10; 36,483 shares at $28.18; 251,518 shares at $25.22; and 24,579 shares at $25.12. After these trades, 779,652 shares were beneficially owned indirectly. Prices reflect weighted averages across multiple trades within stated ranges. The shares are held directly by RA Capital Healthcare Fund, L.P., with beneficial ownership disclaimed except to the extent of pecuniary interest.
Vor Biopharma (VOR): Insider share sales reported by 10% owner/director affiliates. Entities associated with RA Capital reported open-market sales of common stock on three dates. On 10/23/2025, 76,880 shares were sold at $28.01 (weighted average). On 10/24/2025, 53,345 shares were sold at $28.01 (weighted average). On 10/27/2025, 90,941 shares were sold at $28.12 (weighted average).
After these transactions, 1,180,060 shares were beneficially owned indirectly. The filing identifies the reporting persons as RA Capital Management, L.P., RA Capital Management GP, LLC, RA Capital Healthcare Fund, L.P., and individuals including Dr. Peter Kolchinsky and Mr. Rajeev Shah, with holdings held directly by the Fund. Footnotes note weighted-average pricing across ranges and that certain parties disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) insiders affiliated with RA Capital reported open‑market sales of common stock on 10/20/2025 and 10/21/2025. Transactions included 70,366 shares at a weighted average price of $29.63 (range $29.045–$30.025), 6,553 shares at $30.12 (range $30.05–$30.26), and 25,027 shares at $28.11 (range $28.00–$28.475) held indirectly by the RA Capital Healthcare Fund. The RA Capital Nexus Fund sold 13,817 shares at $29.63 and 1,287 shares at $30.12.
Following these transactions, the Healthcare Fund beneficially owned 1,401,226 shares indirectly; the Nexus Fund held 0 shares. The filing was made by more than one reporting person. Reporting persons are noted as Director and 10% Owner and disclaim beneficial ownership except to the extent of pecuniary interest.
Vor Biopharma (VOR) director Reid Hoffman reported open‑market sales of common stock. On 10/17/2025, sales included 24,689 shares at a weighted average price of $30.2207 (executed in multiple trades ranging from $30.00–$30.88) and a separate trade of 1,028 shares at $31.00. Additional sales were 11,616 shares on 10/20/2025 at a weighted average price of $30.0535 (range $30.00–$30.27) and 200 shares on 10/21/2025 at $30.075.
Following these transactions, the filing reports 1,166,909 shares beneficially owned. The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner by virtue of shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his pecuniary interest.
Vor Biopharma (VOR): Form 4 insider sales reported. A reporting group including Reprogrammed Interchange LLC sold a total of 73,676 shares of Vor Biopharma common stock on 10/15/2025 and 10/16/2025. The transactions were executed at weighted average prices of $31.0496, $32.0459, $32.7733, and $30.4548.
Following these sales, 1,204,442 shares were beneficially owned as reported after the final transaction. The securities are held by Reprogrammed Interchange LLC; per the disclosure, Reid Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest, and he disclaims beneficial ownership except to the extent of his pecuniary interest. Each sale was executed in multiple trades within disclosed price ranges.
Vor Biopharma (VOR) disclosed insider sales by affiliates of RA Capital on multiple dates. The filing lists open-market sales (Code S) on 10/15/2025, 10/16/2025, and 10/17/2025 at weighted average prices within disclosed ranges. Examples include sales at $30.55 and $31.17 on 10/15, at $29.32 and $30.36 on 10/16, and at $29.12, $30.28, and $31.00 on 10/17.
Following the reported transactions, the table shows beneficially owned amounts of 1,503,172 shares for the Fund and 15,104 shares for the Nexus Fund, each reported as indirectly held. The report notes the issuer’s 1-for-20 reverse stock split on September 18, 2025, and that the reporting persons are identified as a Director and 10% Owner.
Vor Biopharma (VOR) insider filing reports open‑market sales by an affiliate of director Reid Hoffman totaling 96,657 shares across 10/10–10/14/2025, executed at weighted average prices disclosed in the filing. Following these transactions, 1,278,118 shares were beneficially owned.
The securities are held by Reprogrammed Interchange LLC; Mr. Hoffman may be deemed a beneficial owner through shared control and indirect pecuniary interest and disclaims beneficial ownership except to the extent of his interest. The filing was made by more than one reporting person.
Vor Biopharma Inc. (VOR) insiders reported multiple open-market sales of common stock on 10/08/2025 and 10/09/2025. The filings show four sale transactions totaling 124,146 shares disposed at weighted-average prices ranging from $31.9181 to $34.3391. After these transactions, the reported beneficial ownership held by Reprogrammed Interchange LLC and attributed to Reid Hoffman fell to 1,374,775 shares (direct/indirect holdings by Reprogrammed). The Form 4 includes explanations that the reported prices are weighted averages from multiple trades and offers to provide trade-level detail on request. The document is signed by Reid Hoffman and Frank Huang on 10/10/2025.
Vor Biopharma Inc. reporting persons Reprogrammed Interchange LLC and Reid Hoffman disclosed multiple open-market sales of common stock on 10/06/2025 and 10/07/2025. The filings show four sale lines: 17,760 shares at a weighted average price of $36.0018, 34,847 shares at $37.1213, 18,156 shares at $37.7743, and 27,624 shares at $33.8369. After these transactions, the reporting entity held 1,498,921 shares directly.
The document clarifies that the reported prices are weighted averages from multiple trades and that Mr. Hoffman may be deemed an indirect beneficial owner of the shares held by Reprogrammed but disclaims ownership except for his pecuniary interest. Signatures for Reid Hoffman and Frank Huang (Manager of Reprogrammed Interchange LLC) appear with dates of 10/08/2025.